--- schema_version: "secwatch.filing_event.v1" accession: "0001651308-26-000017" form_type: "8-K" ticker: "ONC" cik: "0001651308" company_name: "BeOne Medicines Ltd." filed_at: "2026-06-11T20:13:24+00:00" generated_at: "2026-06-11T20:14:53.492345+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.4 calibrated_materiality_score: 0.4 confidence: "high" source: SEC EDGAR --- # BeOne Medicines shareholders approve 75.4M share increase in 2016 incentive plan ## Summary - Shareholders approved Fifth Amended 2016 Plan, adding 75,400,000 ordinary shares; and Sixth Amended 2018 ESPP, adding 3,250,000 ordinary shares. - Four directors (Goller, Krishana, Sanders, Yi) did not stand for re-election; no disagreement with the company. - Directors re-elected included Brandicourt, Dugan, Hooper, Oyler, Riva, Sharp, Wang; new directors Baker, Mooney, Sawyers elected. - Connected Person Placing Authorization for Amgen up to 5-year rolling term passed with 458M for, 331M against, 271M abstentions. - General Mandate to Issue Shares (up to 20% of issued shares) and to Repurchase Shares (up to 10%) both approved. ## SEC filing metadata - accession: 0001651308-26-000017 - form_type: 8-K - ticker: ONC - cik: 0001651308 - company_name: BeOne Medicines Ltd. - filed_at: 2026-06-11T20:13:24+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.4 - calibrated_materiality_score: 0.4 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/bgne-20260611.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001651308-26-000017 - JSON: https://secwatch.observer/filing/0001651308-26-000017.json - Plain text: https://secwatch.observer/filing/0001651308-26-000017.txt ## Key facts - Executive change Ranjeev Krishana departed as Director at BeOne Medicines Ltd.. - Action: did not stand for re-election - Role: Director source text: Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Executive change Qingqing Yi departed as Director at BeOne Medicines Ltd.. - Action: did not stand for re-election - Role: Director source text: Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Executive change Corazon (Corsee) D. Sanders departed as Director at BeOne Medicines Ltd.. - Action: did not stand for re-election - Role: Director source text: Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Executive change Michael Goller departed as Director at BeOne Medicines Ltd.. - Action: did not stand for re-election - Role: Director source text: Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, for fiscal year ended December 31, 2025 at the 2026-06-11 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, for fiscal year ended December 31, 2025: Votes For Votes Against Abstentions Broker Non-Votes 975,327,100 52,877,460 32,815,949 — Accordingly, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, was approved. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to approve the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 at the 2026-06-11 meeting. - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to approve the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025: Votes For Votes Against Abstentions Broker Non-Votes 1,026,904,777 175,000 33,940,732 — Accordingly, the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 were approved. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director for a at the 2026-06-11 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director for a term extending until completion of the 2027 annual general meeting: Nominee Votes For Votes Against Abstentions Broker Non-Votes Dr. Olivier Brandicourt 1,022,508,944 5,736,979 32,780,986 — Dr. Margaret Dugan 1,011,658,169 16,567,756 32,794,584 — Mr. Anthony C. Hooper 997,703,483 29,570,339 33,746,687 — Mr. John V. Oyler 1,013,945,040 12,727,593 34,347,876 — Dr. Alessandro Riva 708,200,626 320,024,909 32,794,974 — Ms. Shalini Sharp 998,811,368 28,636,943 33,572,198 — Dr. Xiaodong Wang 1,022,595,038 5,650,686 32,774,785 — Dr. Felix J. Baker 856,267,633 171,971,786 32,781,090 — Ms. Elizabeth F. Mooney 1,028,073,956 152,008 32,794,545 — Dr. Charles L. Sawyers 1,028,075,907 146,090 32,804,912 — evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to elect Schweiger Advokatur/Notariat as the Independent Voting Representative for a term extending until completion of the 2027 annual general meeting at the 2026-06-11 meeting. - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to elect Schweiger Advokatur/Notariat as the Independent Voting Representative for a term extending until completion of the 2027 annual general meeting: Votes For Votes Against Abstentions Broker Non-Votes 1,028,087,301 150,289 32,789,319 — Accordingly, Schweiger Advokatur/Notariat was elected as the Independent Voting Representative. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to approve the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period at the 2026-06-11 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to approve the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period: Votes For Votes Against Abstentions Broker Non-Votes 980,858,936 47,367,478 32,793,555 — Accordingly, the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period was approved. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to re-elect Dr. Margaret Dugan and to elect Ms. Elizabeth F. Mooney to serve as a member of the Compensation Committee of the Board of Directors for a term extending until the 2027 annual general meeting at the 2026-06-11 meeting. - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to re-elect Dr. Margaret Dugan and to elect Ms. Elizabeth F. Mooney to serve as a member of the Compensation Committee of the Board of Directors for a term extending until the 2027 annual general meeting: Nominee Votes For Votes Against Abstentions Broker Non-Votes Dr. Margaret Dugan 1,012,836,634 15,408,489 32,781,786 — Ms. Elizabeth F. Mooney 1,028,055,025 172,249 32,799,635 — Accordingly, each of the nominees listed above was elected to serve as a member of the Compensation Committee of the Board of Directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to re-elect Mr. John V. Oyler as Chairman of the Board of Directors for a term extending until completion of the 2027 annual general meeting at the 2026-06-11 meeting. - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to re-elect Mr. John V. Oyler as Chairman of the Board of Directors for a term extending until completion of the 2027 annual general meeting: Votes For Votes Against Abstentions Broker Non-Votes 939,342,084 88,905,363 32,779,462 — Accordingly, Mr. John V. Oyler was re-elected to serve as Chairman of the Board of Directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to ratify the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 and to re-elect Ernst & Young AG as the Company's statutory auditor for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to ratify the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 and to re-elect Ernst & Young AG as the Company's statutory auditor for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions Broker Non-Votes 1,052,800,458 8,153,634 72,817 — Accordingly, the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors was ratified and Ernst & Young AG was re-elected as the Company's statutory auditor. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to approve the appropriation of the accumulated loss for fiscal year 2025 at the 2026-06-11 meeting. - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to approve the appropriation of the accumulated loss for fiscal year 2025: Votes For Votes Against Abstentions Broker Non-Votes 1,028,050,311 180,369 32,789,829 — Accordingly, the appropriation of the accumulated loss for fiscal year 2025 was approved. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to authorize the Board of Directors to fix the auditors' compensation for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting. - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to authorize the Board of Directors to fix the auditors' compensation for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions Broker Non-Votes 1,022,450,031 3,162,724 35,208,860 — Accordingly, the Board of Directors was authorized to fix the auditors' compensation for the fiscal year ending December 31, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm - Shareholder Votes BeOne Medicines Ltd. shareholders approved Proposal to discharge the members of the Board of Directors and the Executive Management Team from liability for activities during the applicable period under Swiss law at the 2026-06-11 meeting. - Outcome: passed - Meeting: 2026-06-11 source text: Proposal to discharge the members of the Board of Directors and the Executive Management Team from liability for activities during the applicable period under Swiss law: Votes For Votes Against Abstentions Broker Non-Votes 816,696,880 2,683,088 177,864,348 — Accordingly, the members of the Board of Directors and the Executive Management Team were discharged from liability for such activities during the applicable period. evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/0001651308-26-000017-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.